(Q31155412)

29 June 2017

Clinical practice with anti-dementia drugs: A revised (third) consensus statement from the British Association for Psychopharmacology (English)

1 reference

29 June 2017

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28103749%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Clive Holmes

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28103749%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Gill Livingston

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28103749%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Ian G. McKeith

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28103749%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Elizabeth L Sampson

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28103749%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

John-Paul Taylor

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28103749%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

13

Alan Thomas

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28103749%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

4

Roy Jones

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28103749%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

author name string

Matthew Jones

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28103749%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Peter Mittler

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28103749%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Peter Passmore

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28103749%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Louise Robinson

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28103749%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Alistair Burns

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28103749%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

Craig Ritchie

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28103749%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

language of work or name

English

0 references

publication date

1 December 2016

1 reference

Journal of Psychopharmacology

29 June 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28103749%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

volume

31

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28103749%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28103749%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

page(s)

147-168

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28103749%20AND%20SRC:MED&resulttype=core&format=json

Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial.

10 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

Results of a follow-up study to the randomized Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

Non-degenerative mild cognitive impairment in elderly people and use of anticholinergic drugs: longitudinal cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

Safety, tolerability, and efficacy of PBT2 in Huntington's disease: a phase 2, randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

Galantamine treatment of vascular dementia: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

Health service utilization by Alzheimer's disease patients: a 2-year follow-up of primary versus subspecialty care

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

Understanding the challenges to implementing case management for people with dementia in primary care in England: a qualitative study using Normalization Process Theory.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

Pharmacological prevention and treatment of vascular dementia: approaches and perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

Management of dementia with a cerebrovascular component

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

Non-invasive brain stimulation to assess and modulate neuroplasticity in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

Comprehensive treatment of dementia with Lewy bodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

Memantine in patients with frontotemporal lobar degeneration: a multicentre, randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

Dementia before death in ageing societies--the promise of prevention and the reality

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

Medial temporal lobe atrophy on MRI differentiates Alzheimer's disease from dementia with Lewy bodies and vascular cognitive impairment: a prospective study with pathological verification of diagnosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

Etanercept in Alzheimer disease: A randomized, placebo-controlled, double-blind, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

The Association Between Anticholinergic Medication Burden and Health Related Outcomes in the 'Oldest Old': A Systematic Review of the Literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

A comparison of 99mTc-exametazime and 123I-FP-CIT SPECT imaging in the differential diagnosis of Alzheimer's disease and dementia with Lewy bodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

Randomized, double-blind, parallel-group, 48-week study for efficacy and safety of a higher-dose rivastigmine patch (15 vs. 10 cm²) in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

Ginkgo biloba for prevention of dementia: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

Donepezil in patients with subcortical vascular cognitive impairment: a randomised double-blind trial in CADASIL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

A randomized placebo-controlled trial of Ginkgo biloba for the prevention of cognitive decline.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

Revising the definition of Alzheimer's disease: a new lexicon.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

Transcranial magnetic stimulation and transcranial direct current stimulation: treatments for cognitive and neuropsychiatric symptoms in the neurodegenerative dementias?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

Rivastigmine for dementia associated with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

Clinical diagnostic criteria for dementia associated with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

Oxytocin for frontotemporal dementia: a randomized dose-finding study of safety and tolerability

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

The impact of anticholinergic burden in Alzheimer's dementia-the LASER-AD study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

Anticholinergic medication use and cognitive impairment in the older population: the medical research council cognitive function and ageing study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

Efficacy and tolerability of Ginkgo biloba extract EGb 761® in dementia: a systematic review and meta-analysis of randomized placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

Quinacrine treatment trial for sporadic Creutzfeldt-Jakob disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

Syncope and its consequences in patients with dementia receiving cholinesterase inhibitors: a population-based cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

Advances in the treatment of cognitive impairment in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

Classification of primary progressive aphasia and its variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

Doxycycline in Creutzfeldt-Jakob disease: a phase 2, randomised, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

Pathology in primary progressive aphasia syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

Neuroinflammation in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

Is high homocysteine level a risk factor for cognitive decline in elderly? A systematic review, meta-analysis, and meta-regression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

Integrating palliative medicine into the care of persons with advanced dementia: identifying appropriate medication use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

EFNS guidelines for the diagnosis and management of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

Transcranial direct current stimulation: five important issues we aren't discussing (but probably should be).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

Quantitative Review Finds No Evidence of Cognitive Effects in Healthy Populations From Single-session Transcranial Direct Current Stimulation (tDCS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

Donepezil and memantine for moderate-to-severe Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

Nursing home placement in the Donepezil and Memantine in Moderate to Severe Alzheimer's Disease (DOMINO-AD) trial: secondary and post-hoc analyses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

Effects of noninvasive brain stimulation on cognitive function in healthy aging and Alzheimer's disease: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

Efficacy of treating pain to reduce behavioural disturbances in residents of nursing homes with dementia: cluster randomised clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

Efficacy and tolerability of a once daily formulation of Ginkgo biloba extract EGb 761® in Alzheimer's disease and vascular dementia: results from a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled, confirmatory phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

Is there a risk of bleeding associated with standardized Ginkgo biloba extract therapy? A systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

Therapeutic effects of non-invasive brain stimulation with direct currents (tDCS) in neuropsychiatric diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

Ginkgo biloba for mild to moderate dementia in a community setting: a pragmatic, randomised, parallel-group, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

Hormone therapy, dementia, and cognition: the Women's Health Initiative 10 years on.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

Effectiveness of dementia follow-up care by memory clinics or general practitioners: randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

CSF phosphorylated tau in the diagnosis and prognosis of mild cognitive impairment and Alzheimer's disease: a meta-analysis of 51 studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

Different responses to rivastigmine in subcortical vascular dementia and multi-infarct dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

Long-term donepezil use for dementia with Lewy bodies: results from an open-label extension of Phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

Diagnostic rates and treatment of dementia before and after launch of a national dementia policy: an observational study using English national databases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

Role of imaging techniques in the diagnosis of dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

Clinical practice with anti-dementia drugs: a revised (second) consensus statement from the British Association for Psychopharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

Amyloid imaging for dementia in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

Vascular cognitive impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

18F-FDG PET and perfusion SPECT in the diagnosis of Alzheimer and Lewy body dementias.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

Efficacy and safety of nimodipine in subcortical vascular dementia: a randomized placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

Souvenaid reduces behavioral deficits and improves social cognition skills in frontotemporal dementia: a proof-of-concept study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

Cognitive, global, and functional benefits of donepezil in Alzheimer's disease and vascular dementia: results from large-scale clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

Absence of cholinergic deficits in "pure" vascular dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

Vascular care in patients with Alzheimer's disease with cerebrovascular lesions-a randomized clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

The PREVENT study: a prospective cohort study to identify mid-life biomarkers of late-onset Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

Development of interventions for the secondary prevention of Alzheimer's dementia: the European Prevention of Alzheimer's Dementia (EPAD) project

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

Primary care and dementia: 2. Long-term care at home: psychosocial interventions, information provision, carer support and case management.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

Current concepts in vascular cognitive impairment and pharmacotherapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

Diagnostic criteria for vascular cognitive disorders: a VASCOG statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

Anticholinergic burden quantified by anticholinergic risk scales and adverse outcomes in older people: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

Moving Us Toward a Theory of Individual Quality of Life.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

Efficacy of a medical food in mild Alzheimer's disease: A randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

EFNS-ENS/EAN Guideline on concomitant use of cholinesterase inhibitors and memantine in moderate to severe Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

A randomized, double-blind, placebo-controlled trial of two doses of Ginkgo biloba extract in dementia of the Alzheimer's type.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

Cognitive decline in older persons initiating anticholinergic medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

The S-Connect study: results from a randomized, controlled trial of Souvenaid in mild-to-moderate Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

Choline acetyltransferase activity in vascular dementia and stroke.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

Pharmacological Management of Lewy Body Dementia: A Systematic Review and Meta-Analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

Effects of a non-focal plasticity protocol on apathy in moderate Alzheimer's disease: a randomized, double-blind, sham-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

The effect of a disease management intervention on quality and outcomes of dementia care: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

Efficacy of Ginkgo biloba extract EGb 761(®) in dementia with behavioural and psychological symptoms: A systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

Effectiveness of standardized ginkgo biloba extract on cognitive symptoms of dementia with a six-month treatment: a bivariate random effect meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies: systematic review with meta-analysis and trial sequential analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

Effects of Ginkgo biloba in dementia: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

Tailored educational intervention for primary care to improve the management of dementia: the EVIDEM-ED cluster randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

Diagnostic accuracy of 123I-meta-iodobenzylguanidine myocardial scintigraphy in dementia with Lewy bodies: a multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

Improving end-of-life care for people with dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881116680924

21 January 2018

Identifiers

DOI

10.1177/0269881116680924

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28103749%20AND%20SRC:MED&resulttype=core&format=json

10 June 2020

1 reference